SCHEMBL6030375

SCHEMBL6030375

CCCCCCCCOC(=O)c1sc(NC(=O)OCc2ccccc2)c(C(=O)OC(C)(C)C)c1C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
POLB P06746 2/20 0.45
PKM P14618 1/20 0.43
ALDH1A1 P00352 8/20 0.43
TSHR P16473 3/20 0.43
CYP3A4 P08684 1/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MBOAT4 Q96T53 1/20 0.41
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
BRAF P15056 1/20 0.39
SYK P43405 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029726 0.90 MAPT (0.48) MAPTPOLBPKMALDH1A1TSHR
SCHEMBL6030718 0.88 PKM (0.52) MAPTPOLBPKMALDH1A1TSHR
SCHEMBL6030376 0.88 PKM (0.52) MAPTPOLBPKMALDH1A1TSHR
SCHEMBL6030379 0.87 ALDH1A1 (0.42) MAPTPOLBALDH1A1L3MBTL1MBOAT4
SCHEMBL6029684 0.85 MAPT (0.45) MAPTPOLBPKMALDH1A1TSHR
SCHEMBL6031521 0.85 MAPT (0.45) MAPTPOLBPKMALDH1A1TSHR
SCHEMBL6030356 0.85 MAPT (0.45) MAPTPOLBPKMALDH1A1TSHR
SCHEMBL6031142 0.85 MAPT (0.45) MAPTPOLBPKMALDH1A1TSHR
SCHEMBL6030153 0.85 MAPT (0.44) MAPTPOLBPKMALDH1A1L3MBTL1
SCHEMBL6030389 0.85 ALDH1A1 (0.43) MAPTALDH1A1TSHRCYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL MAPT 4105/4885POLB 2788/4885PKM 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.